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Single-dose azithromycin to treat latent yaws
Yaws, caused by Treponema pallidum subsp pertenue, was 
the first disease to be targeted for eradication by WHO.1 
As with other treponemal infections, such as syphilis, 
some people develop latent infection. These individuals 
have positive serological test results for yaws but no 
clinical signs of disease. Importantly, latent yaws can 
relapse, which most frequently occurs in the first 5 years 
after infection,2 and, therefore, these people represent an 
important source of reinfection in endemic communities.
In 2012, WHO developed a strategy for yaws 
eradication3 based on mass treatment of communities 
with single-dose oral azithromycin. WHO’s previous 
yaws eradication campaign, in the 1950–60s, was 
based on mass treatment with long-acting injectable 
penicillin. Although this approach substantially reduced 
the worldwide prevalence of yaws, it did not result in 
eradication. Failure to identify and treat latent cases 
adequately in endemic communities was probably a 
crucial factor in this outcome.4
The initial studies of single-dose azithromycin 
for the treatment of yaws focused on patients with 
active primary and secondary yaws,5,6 and showed 
high clinical and serological cure rates 6 months after 
treatment. Subsequent community studies showed 
similar reduced prevalence of active yaws with mass 
treatment, plus apparent reductions in the prevalence 
of latent yaws.7,8 All these studies, however, were 
limited by short follow-up, which has probably led 
to underestimation of the true effects of treatment, 
because rapid plasma reagin (RPR) titres can take 
12–24 months to fall by two dilutions or revert to 
negative after successful treatment, particularly in 
people with latent yaws.9
In The Lancet Global Health, Oriol Mitjà and colleagues10 
provide the most comprehensive data so far on the 
effects of single-dose azithromycin on latent yaws. 
They enrolled 311 participants with suspected yaws 
and RPR titres of 1:8 or higher into a prospective cohort 
study. Importantly, the researchers used molecular 
diagnostics to differentiate individuals who were 
seropositive for yaws and had skin lesions containing 
DNA of T pallidum (active yaws) from those whose 
skin lesions were caused by other organisms, such as 
Haemophilus ducreyi (latent yaws). A particular strength 
of the study is the long duration of follow-up; the 
primary end point was serological cure 24 months 
after treatment. 273 individuals (108 with active 
yaws and 165 with latent yaws) completed follow-
up. The proportions of patients with serological cure 
at 24 months were similar in patients with active and 
latent yaws. At 6 months, serological cure was seen 
in 88% and 83% of participants, respectively, but at 
24 months, the proportions had increased to 94% and 
92%, respectively. This marked increase in the latent 
yaws group underscores the usefulness of the long 
follow-up in this study.
Several questions remain unanswered by Mitjà and 
colleagues. First, some individuals who did not achieve 
serological cure might have been serofast (ie, cured but 
remained seropositive). The authors excluded people 
with RPR titres lower than 1:8 at baseline, which should 
have kept the number of serofast individuals enrolled to 
a minimum, but could explain why some participants 
had not achieved serological cure by 24 months. No 
test is available to distinguish latent infection from 
serofast status, but such a tool would be useful for 
yaws eradication programmes. Second, participants 
without adequate serological responses might have 
been reinfected during follow-up, but, again, no test 
can distinguish reinfection from serological failure. 
The current study was done within a community 
mass treatment programme, which would have 
minimised but not eliminated the risk of reinfection. 
Third, the serological cure rate at 6 months is lower 
in Ghana than that in Papua New Guinea.5,6 Studies 
with extended follow-up, as in that done by Mitjà and 
colleagues, would be helpful to assess differences in 
cure rates between countries and their underlying 
reasons. Resistance to azithromycin has limited its use 
in the treatment of syphilis and, although resistant 
strains of T pertenue have not yet been reported, it 
remains a concern for yaws elimination programmes. 
Finally, WHO also recommends mass treatment with 
azithromycin for the control of trachoma, but at a 
lower dose than that used for yaws.11 The results of a 
completed trial should provide data on the effectiveness 
of lower-dose azithromycin used to treat active and 
latent yaws to help guide scale up of integrated mass 
drug administration programmes in countries where 
yaws and trachoma are coendemic.
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